Tara M Stanne1, N David Åberg2, Staffan Nilsson2, Katarina Jood2, Christian Blomstrand2, Ulf Andreasson2, Kaj Blennow2, Henrik Zetterberg2, Jörgen Isgaard2, Johan Svensson2, Christina Jern2. 1. From the Department of Medical and Clinical Genetics (T.M.S., C.J.), Department of Internal Medicine (NDÅ, J.I., J.S.), Center of Brain Repair and Rehabilitation (N.D.Å., C.B.), Department for Clinical Neuroscience and Rehabilitation (K.J., C.B.), Department of Psychiatry and Neurochemistry (U.A., K.B., H.Z.), The Sahlgrenska Academy at University of Gothenburg, Gothenburg, Sweden; Chalmers University of Technology, Mathematical Sciences, Gothenburg, Sweden (S.N.); and UCL Institute of Neurology, London, United Kingdom (H.Z.). tara.stanne@gu.se. 2. From the Department of Medical and Clinical Genetics (T.M.S., C.J.), Department of Internal Medicine (NDÅ, J.I., J.S.), Center of Brain Repair and Rehabilitation (N.D.Å., C.B.), Department for Clinical Neuroscience and Rehabilitation (K.J., C.B.), Department of Psychiatry and Neurochemistry (U.A., K.B., H.Z.), The Sahlgrenska Academy at University of Gothenburg, Gothenburg, Sweden; Chalmers University of Technology, Mathematical Sciences, Gothenburg, Sweden (S.N.); and UCL Institute of Neurology, London, United Kingdom (H.Z.).
Abstract
BACKGROUND AND PURPOSE: Brain-derived neurotrophic factor (BDNF) plays important roles in brain plasticity and repair, and it influences stroke outcomes in animal models. Circulating BDNF concentrations are lowered in patients with traumatic brain injury, and low BDNF predicts poor recovery after this injury. We sought to investigate whether circulating concentrations of BDNF are altered in the acute phase of ischemic stroke and whether they are associated with short- or long-term functional outcome. METHODS: Serum concentrations of BDNF were measured in the Sahlgrenska Academy Study on Ischemic Stroke. The main outcomes were modified Rankin Scale (mRS) good (mRS score of 0-2) versus poor (mRS score of 3-6) at 3 months and 2 years after stroke, and good (mRS score of 0-2) versus poor (mRS score of 3-5) at 7 years after stroke. RESULTS: Acute concentrations of BDNF were significantly lower in ischemic stroke cases (n=491) compared with controls (n=513). BDNF concentrations were not significantly associated with 3-month outcome. However, patients with BDNF in the lowest tertile had an increased risk of experiencing a poor outcome both at 2-year and 7-year follow-up, and these associations were independent of vascular risk factors and stroke severity (odds ratio, 2.6; confidence intervals, 1.4-4.9; P=0.002 and odds ratio, 2.1; confidence intervals, 1.1-3.9; P=0.028, respectively). CONCLUSIONS: Circulating concentrations of BDNF protein are lowered in the acute phase of ischemic stroke, and low levels are associated with poor long-term functional outcome. Further studies are necessary to confirm these associations and to determine the predictive value of BDNF in stroke outcomes.
BACKGROUND AND PURPOSE:Brain-derived neurotrophic factor (BDNF) plays important roles in brain plasticity and repair, and it influences stroke outcomes in animal models. Circulating BDNF concentrations are lowered in patients with traumatic brain injury, and low BDNF predicts poor recovery after this injury. We sought to investigate whether circulating concentrations of BDNF are altered in the acute phase of ischemic stroke and whether they are associated with short- or long-term functional outcome. METHODS: Serum concentrations of BDNF were measured in the Sahlgrenska Academy Study on Ischemic Stroke. The main outcomes were modified Rankin Scale (mRS) good (mRS score of 0-2) versus poor (mRS score of 3-6) at 3 months and 2 years after stroke, and good (mRS score of 0-2) versus poor (mRS score of 3-5) at 7 years after stroke. RESULTS: Acute concentrations of BDNF were significantly lower in ischemic stroke cases (n=491) compared with controls (n=513). BDNF concentrations were not significantly associated with 3-month outcome. However, patients with BDNF in the lowest tertile had an increased risk of experiencing a poor outcome both at 2-year and 7-year follow-up, and these associations were independent of vascular risk factors and stroke severity (odds ratio, 2.6; confidence intervals, 1.4-4.9; P=0.002 and odds ratio, 2.1; confidence intervals, 1.1-3.9; P=0.028, respectively). CONCLUSIONS: Circulating concentrations of BDNF protein are lowered in the acute phase of ischemic stroke, and low levels are associated with poor long-term functional outcome. Further studies are necessary to confirm these associations and to determine the predictive value of BDNF in stroke outcomes.
Authors: Nienke Wagenaar; Caroline G M de Theije; Linda S de Vries; Floris Groenendaal; Manon J N L Benders; Cora H A Nijboer Journal: Pediatr Res Date: 2017-11-01 Impact factor: 3.756
Authors: Martin Pedard; Céline Brenière; Nicolas Pernet; Catherine Vergely; Yannick Béjot; Christine Marie Journal: Exp Biol Med (Maywood) Date: 2018-11-24
Authors: Giovanni Pietrogrande; Katarzyna Zalewska; Zidan Zhao; Sarah J Johnson; Michael Nilsson; Frederick R Walker Journal: Transl Stroke Res Date: 2018-08-28 Impact factor: 6.829
Authors: Catherine Madurski; Jessica M Jarvis; Sue R Beers; Amy J Houtrow; Amy K Wagner; Anthony Fabio; Chunyan Wang; Craig M Smith; Lesley Doughty; Keri Janesko-Feldman; Pamela Rubin; Dorothy Pollon; Amery Treble-Barna; Patrick M Kochanek; Ericka L Fink Journal: Neurocrit Care Date: 2021-03-04 Impact factor: 3.532